CA2125667A1 - Fluorocarbon aerosol medicaments - Google Patents

Fluorocarbon aerosol medicaments

Info

Publication number
CA2125667A1
CA2125667A1 CA 2125667 CA2125667A CA2125667A1 CA 2125667 A1 CA2125667 A1 CA 2125667A1 CA 2125667 CA2125667 CA 2125667 CA 2125667 A CA2125667 A CA 2125667A CA 2125667 A1 CA2125667 A1 CA 2125667A1
Authority
CA
Canada
Prior art keywords
salbutamol
tetrafluoroethane
formulation
propellant
physiologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2125667
Other languages
French (fr)
Other versions
CA2125667C (en
Inventor
Rachel Ann Akehurst
Anthony James Taylor
David Andrew Wyatt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Rachel Ann Akehurst
Anthony James Taylor
David Andrew Wyatt
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to GB919126405A priority Critical patent/GB9126405D0/en
Priority to GB9126405.1 priority
Priority to GB919126378A priority patent/GB9126378D0/en
Priority to GB9126378.0 priority
Priority to GB9202522.0 priority
Priority to GB929202522A priority patent/GB9202522D0/en
Priority to PCT/EP1992/002808 priority patent/WO1993011743A1/en
Application filed by Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt, Glaxo Group Limited filed Critical Rachel Ann Akehurst
Publication of CA2125667A1 publication Critical patent/CA2125667A1/en
Application granted granted Critical
Publication of CA2125667C publication Critical patent/CA2125667C/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27265965&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2125667(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Anticipated expiration legal-status Critical
Application status is Expired - Lifetime legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • A61K9/124Aerosols; Foams characterised by the propellant
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/937Dispersion or emulsion

Abstract

This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which consists essentially of particulate medicament selected from the group comprising salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate and physiologically acceptable salts and solvates thereof, said particulate medicament having a particle size of less than 100 microns; and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w of surfactant and with the provisos that when said formulation consists of salbutamol and 1,1,1,2-tetrafluoroethane in a weight ratio of 0.05:18, said salbutamol is in the form of a physiologically acceptable salt and that when said formulation consists of salbutamol, salbutamol sulphate or beclomethasone dipropionate isopropyl alcohol solvate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 (0.866%).
CA 2125667 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments Expired - Lifetime CA2125667C (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GB919126405A GB9126405D0 (en) 1991-12-12 1991-12-12 Medicaments
GB9126405.1 1991-12-12
GB919126378A GB9126378D0 (en) 1991-12-12 1991-12-12 Medicaments
GB9126378.0 1991-12-12
GB929202522A GB9202522D0 (en) 1992-02-06 1992-02-06 Medicaments
GB9202522.0 1992-02-06
PCT/EP1992/002808 WO1993011743A1 (en) 1991-12-12 1992-12-04 Medicaments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002303685A CA2303685C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments

Publications (2)

Publication Number Publication Date
CA2125667A1 true CA2125667A1 (en) 1993-06-24
CA2125667C CA2125667C (en) 2000-06-13

Family

ID=27265965

Family Applications (7)

Application Number Title Priority Date Filing Date
CA002654849A Abandoned CA2654849A1 (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments
CA002303685A Expired - Lifetime CA2303685C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments
CA 2125667 Expired - Lifetime CA2125667C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments
CA002362539A Expired - Fee Related CA2362539C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments
CA002447510A Expired - Lifetime CA2447510C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments
CA002586146A Expired - Lifetime CA2586146C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments
CA002402300A Expired - Lifetime CA2402300C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CA002654849A Abandoned CA2654849A1 (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments
CA002303685A Expired - Lifetime CA2303685C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments

Family Applications After (4)

Application Number Title Priority Date Filing Date
CA002362539A Expired - Fee Related CA2362539C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments
CA002447510A Expired - Lifetime CA2447510C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments
CA002586146A Expired - Lifetime CA2586146C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments
CA002402300A Expired - Lifetime CA2402300C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments

Country Status (28)

Country Link
US (10) US5674472A (en)
EP (8) EP1440686B1 (en)
JP (2) JP3026840B2 (en)
AP (1) AP402A (en)
AT (7) AT373465T (en)
AU (1) AU663904C (en)
BG (3) BG102689A (en)
CA (7) CA2654849A1 (en)
CY (6) CY2134B1 (en)
CZ (1) CZ287039B6 (en)
DE (14) DE69231857T2 (en)
DK (7) DK1440686T3 (en)
ES (7) ES2294386T3 (en)
GE (1) GEP20002253B (en)
GR (1) GR3036476T3 (en)
HK (3) HK1012988A1 (en)
HU (3) HU227383B1 (en)
IL (2) IL104068A (en)
IS (1) IS1709B (en)
MX (1) MX9207205A (en)
NO (3) NO307864B1 (en)
NZ (1) NZ246044A (en)
OA (1) OA9926A (en)
PT (6) PT1440686E (en)
RU (2) RU2129424C1 (en)
SK (1) SK279920B6 (en)
TW (1) TW232654B (en)
WO (1) WO1993011743A1 (en)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5776434A (en) * 1988-12-06 1998-07-07 Riker Laboratories, Inc. Medicinal aerosol formulations
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
ES2180592T3 (en) 1991-06-10 2003-02-16 Schering Corp Free aerosol formulations chlorofluorocarbons.
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
AU663906B2 (en) * 1991-12-12 1995-10-26 Glaxo Group Limited Medicaments
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
ES2123576T3 (en) 1991-12-12 1999-01-16 Glaxo Group Ltd Medicines.
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US20030103907A1 (en) * 1991-12-18 2003-06-05 Schultz Robert K. Suspension aerosol formulations
PT1086688E (en) 1991-12-18 2004-06-30 Minnesota Mining & Mfg Suspended aerosol formulations
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US6013245A (en) * 1995-01-26 2000-01-11 Glaxo Group Limited Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant
US5833950A (en) * 1992-07-31 1998-11-10 Glaxo Group Limited Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate
HU221163B1 (en) * 1992-12-09 2002-08-28 Boehringer Ingelheim Pharma Stabilized medicinal aerosol solution formulations and process for producing them
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
EP0619115A1 (en) * 1993-04-01 1994-10-12 Amgen Inc. Container comprising a metered dose valve and microparticles of a drug for topical treatment of skin disorders
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
PE44995A1 (en) * 1994-01-27 1995-12-18 Schering Corp Mometasone furoate for the treatment of pulmonary diseases and airway
GB9425160D0 (en) 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
GB9507768D0 (en) * 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
US20030103906A1 (en) * 1997-10-14 2003-06-05 Smithkline Beecham Corporation Metered dose inhaler having internal surfaces coated with fluorocarbon polymer
US6149892A (en) 1995-04-14 2000-11-21 Glaxowellcome, Inc. Metered dose inhaler for beclomethasone dipropionate
AT347391T (en) * 1995-04-14 2006-12-15 Smithkline Beecham Corp Dosing inhaler for fluticasone propionate
AU710382B2 (en) 1995-04-14 1999-09-16 Glaxo Wellcome Inc. Metered dose inhaler for albuterol
PT820323E (en) * 1995-04-14 2004-03-31 Smithkline Beecham Corp Salmeterol dosing inhaler
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
GB9526392D0 (en) * 1995-12-22 1996-02-21 Glaxo Group Ltd Medicaments
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
DE19652790A1 (en) * 1996-12-18 1998-06-25 Hermes Fabrik Pharm Praeparate pharmaceutical preparations
GB9626960D0 (en) * 1996-12-27 1997-02-12 Glaxo Group Ltd Valve for aerosol container
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
EP0998300A1 (en) * 1997-03-18 2000-05-10 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US5891420A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
US6264923B1 (en) 1998-05-13 2001-07-24 3M Innovative Properties Company Medicinal aerosol formulation of ciclesonide and related compounds
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
GB2332372B (en) * 1997-12-08 2002-08-14 Minnesota Mining & Mfg Pharmaceutical aerosol compositions
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
DZ2947A1 (en) 1998-11-25 2004-03-15 Chiesi Farma Spa pressurized meter dose inhaler.
US6261539B1 (en) * 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US20100197719A1 (en) * 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
JP2002541183A (en) 1999-04-14 2002-12-03 グラクソ グループ リミテッド Medicinal aerosol formulations
IT1313553B1 (en) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulations optimized consist of dasomministrare steroids solutions for inhalation.
GB2385596B (en) * 1999-09-11 2004-03-03 Glaxo Group Ltd Container for pharmaceutical formulation of fluticasone propionate
JP2003509359A (en) 1999-09-11 2003-03-11 グラクソ グループ リミテッド The pharmaceutical formulations of fluticasone propionate
GB9924992D0 (en) * 1999-10-21 1999-12-22 Glaxo Group Ltd Pharmaceutical aerosol formulations
WO2001047493A1 (en) * 1999-12-24 2001-07-05 Glaxo Group Limited Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
IT1317846B1 (en) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulations containing an anticholinergic drug for chronic obstructive pulmonary disease trattamentodella.
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
CA2382133C (en) 2000-05-10 2010-11-23 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
CN1213732C (en) 2000-05-22 2005-08-10 奇斯药制品公司 Stable pharmaceutical solution formulations for pressurised metered dose inhalers
CZ305288B6 (en) * 2000-05-23 2015-07-22 Glaxo Group Limited Container with sealed valve
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
US6994781B2 (en) * 2000-07-07 2006-02-07 Baxter International Inc. Medical system, method and apparatus employing MEMS
AR030516A1 (en) * 2000-08-31 2003-08-20 Glaxo Group Ltd Using a combination of salmeterol and fluticasone
FI20002177A0 (en) * 2000-10-02 2000-10-02 Orion Yhtymae Oyj New combination asthma treatment
FI20002215A0 (en) 2000-10-06 2000-10-06 Orion Yhtymae Oyj composite particles
FI20002216A0 (en) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Composite particles to treat asthma
AT430558T (en) 2000-10-27 2009-05-15 Baxter Healthcare Sa Preparation of micro beads
US20040050960A1 (en) * 2000-12-22 2004-03-18 Godfrey Anne Pauline Metered dose inhaler for salemeterol xinafoate
CA2433280C (en) * 2000-12-27 2010-09-21 Salus Pharma, Inc. Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
US7214364B2 (en) * 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
DE10104370A1 (en) * 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Pharmaceutical compositions having reduced side effects
GB0106046D0 (en) 2001-03-12 2001-05-02 Glaxo Group Ltd Canister
BR0208012A (en) * 2001-03-20 2004-03-02 Glaxo Group Ltd Uses of at least two drug and HFA propellant and at least one farmaceêutica composition, and packaged for treating asthma inhaler
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US6455028B1 (en) 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
BR0209986A (en) * 2001-05-25 2004-04-06 Pfizer 2A agonist in combination with an anticholinergic agent for the treatment of obstructive airway diseases
AT267591T (en) 2001-07-02 2004-06-15 Chiesi Farma Spa Optimized tobramycin formulation for aerosol-formation
GB0124523D0 (en) * 2001-10-12 2001-12-05 Glaxo Group Ltd Pharmaceutical combination
US7931022B2 (en) * 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
JP2003221335A (en) 2001-10-26 2003-08-05 Dey Lp Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptom of chronic obstructive pulmonary disease
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
MXPA04005865A (en) 2001-12-19 2004-09-13 Nektar Therapeutics Pulmonary delivery of aminoglycosides.
AU2003210517A1 (en) 2002-02-04 2003-09-02 Elan Pharma International, Ltd. Drug nanoparticles with lysozyme surface stabiliser
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
WO2003088961A1 (en) * 2002-04-19 2003-10-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US9308199B2 (en) * 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
US20060247216A1 (en) * 2002-10-25 2006-11-02 Haj-Yehia Abdullah I Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
WO2004060260A2 (en) * 2002-12-18 2004-07-22 Glaxo Group Limited Drug delivery system with vented mouthpiece
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US7459146B2 (en) 2003-05-30 2008-12-02 3M Innovative Properties Company Stabilized aerosol dispersions
WO2004110460A1 (en) 2003-06-13 2004-12-23 Altana Pharma Ag Formoterol and ciclesonide combination
SE527069C2 (en) * 2003-06-19 2005-12-13 Mederio Ag Method and device for administration of medicament powder
SE526509C2 (en) * 2003-06-19 2005-09-27 Microdrug Ag Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses
SE527189C2 (en) * 2003-06-19 2006-01-17 Microdrug Ag Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses
SE527190C2 (en) * 2003-06-19 2006-01-17 Microdrug Ag Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses
SE527200C2 (en) * 2003-06-19 2006-01-17 Microdrug Ag Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050043343A1 (en) * 2003-07-28 2005-02-24 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
AU2004272077A1 (en) * 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
ES2452691T3 (en) 2003-09-16 2014-04-02 Takeda Gmbh Use of ciclesonide for the treatment of respiratory diseases
CA2542530A1 (en) * 2003-10-20 2005-05-12 Schering Corporation Pharmaceutical aerosol compositions
SE0303269A (en) * 2003-12-03 2005-06-04 Microdrug Ag medical product
SE0303570A (en) * 2003-12-03 2005-06-04 Microdrug Ag Moisture-sensitive medical product
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
KR101297061B1 (en) 2004-07-02 2013-08-19 베링거 인겔하임 인터내셔날 게엠베하 Aerosol suspension formulations containing tg 227 ea or tg 134 a as a propellant
PE20061162A1 (en) * 2004-12-06 2006-10-14 Smithkline Beecham Corp Olefinic compounds derived from 8-azoniabicyclo [3.2.1] octane
EP2311793A1 (en) * 2004-12-17 2011-04-20 Cipla Ltd. Crystalline levosalbutamol sulphate (Form II)
JP2008546634A (en) * 2005-03-16 2008-12-25 ハネウェル・インターナショナル・インコーポレーテッド Pharmaceutical delivery formulations, devices and methods
CA2607391A1 (en) * 2005-04-23 2006-11-02 Boehringer Ingelheim International Gmbh Combination of medicaments to be inhaled, containing a betamimetic agent and a steroid in addition to an anticholinergic agent
US20060239935A1 (en) * 2005-04-23 2006-10-26 Boehringer Ingelheim International Gmbh Compositions for inhalation
TWI274641B (en) * 2005-08-30 2007-03-01 Rexon Ind Corp Ltd Cutting machine
EP1991532B1 (en) 2006-02-24 2017-01-11 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
DE102006017320A1 (en) 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
JP5825757B2 (en) 2007-02-11 2015-12-02 マップ・ファーマシューティカルズ・インコーポレイテッド Method of therapeutic administration of DHE that allows rapid relief of migraine while minimizing side effect profile
GB0712454D0 (en) 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions
GB0716026D0 (en) 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
WO2009088553A1 (en) 2007-10-22 2009-07-16 Board Of Regents, The University Of Texas System Dry powder drug delivery formulations, methods of use, and devices therefore
US20110003897A1 (en) * 2007-11-02 2011-01-06 Wayne State University Methods of engineering polar drug particles with surface-trapped hydrofluoroalkane-philes
US8227027B2 (en) * 2007-12-07 2012-07-24 Presspart Gmbh & Co. Kg Method for applying a polymer coating to an internal surface of a container
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
EP2529686B1 (en) 2008-05-09 2015-10-14 Holaira, Inc. System for treating a bronchial tree
PE20110924A1 (en) 2009-01-23 2011-12-24 Rigel Pharmaceuticals Inc Derivatives of 2, 4-diamino-pyrimidine n2, n4-disubstituted as JAK3 inhibitors
WO2010141834A1 (en) * 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
CN104856757B (en) 2009-10-27 2017-06-23 赫莱拉公司 Delivery apparatus with coolable energy transmitting device
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
CN106618731A (en) 2009-11-11 2017-05-10 赫莱拉公司 Systems, apparatuses, and methods for treating tissue and controlling stenosis
AR079451A1 (en) 2009-12-18 2012-01-25 Nycomed Gmbh Compounds 3,4,4a, 10b-tetrahydro-1H-thiopyrano [4,3-c] isoquinoline
EP2528601A1 (en) 2010-01-26 2012-12-05 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Compositions and methods for prevention and treatment of pulmonary hypertension
CN102416179B (en) 2010-09-28 2014-05-07 益得生物科技股份有限公司 Inhaled compound composition for asthma
TWI399202B (en) 2011-03-17 2013-06-21 Intech Biopharm Ltd The preparation for formulation composition and manufacturing processes of metered dose inhalers treated respiratory diseases
US20140113877A1 (en) 2011-06-15 2014-04-24 Takeda Gmbh Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c] isoquinoline compounds
BR112013031791A2 (en) 2011-06-17 2017-01-31 Takeda Gmbh phthalazinone-pyrrolopyrimidinecarboxamide derivatives
GB201118188D0 (en) * 2011-10-21 2011-12-07 3M Innovative Properties Co Manufacture of medicinal aerosol canisters
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
EP2828241B1 (en) 2012-03-23 2018-09-12 Mateon Therapeutics, Inc. Compositions and methods for inhibition of cathepsins
RU2494730C1 (en) * 2012-03-27 2013-10-10 Шолекс Девелопмент Гмбх Inhalation preparation for treating respiratory diseases containing micronised salmeterol xinafoate and micronised fluticasone propionate as active substances and method for preparing it
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
EP3174522A1 (en) 2014-07-29 2017-06-07 3M Innovative Properties Company Method of preparing a pharmaceutical composition
WO2018069210A1 (en) 2016-10-10 2018-04-19 Takeda Gmbh Tetrahydrofuro[3,4-c]isoquinolines as inhibitors of pde4

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (en) * 1956-03-21 1900-01-01
US2885427A (en) * 1956-11-15 1959-05-05 Dow Chemical Co Fluorination of trichloroethylene
BE556587A (en) * 1957-01-31 1957-04-11
BE629985A (en) 1962-11-29
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
FR4699M (en) 1964-07-17
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) * 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US3897779A (en) * 1973-06-27 1975-08-05 American Cyanamid Co Triamcinolone acetonide inhalation therapy
US3809294A (en) * 1973-06-27 1974-05-07 American Cyanamid Co Dispensing lung contacting powdered medicaments
US4044125A (en) * 1975-07-18 1977-08-23 Eli Lilly And Company Method of stabilizing acetylsalicylic acid in the presence of d-propoxyphene hydrochloride and compositions thereof
US4405598A (en) * 1976-01-30 1983-09-20 Fisons, Limited Composition for treating asthma
IL51314A (en) * 1976-01-30 1980-03-31 Fisons Ltd Disodium cromoglycate of low moisture content and pharmaceutical compositions containing it
US4117958A (en) * 1976-12-27 1978-10-03 Spitzer Joseph G Vapor tap valve for aerosol containers used with flammable propellants
NL7708731A (en) 1976-08-13 1978-02-15 Montedison Spa A process for the preparation of new propellant compositions for aerosols.
GB2088877B (en) 1980-02-15 1984-07-04 Glaxo Group Ltd Androstane 17 carbothioates
US4335121A (en) 1980-02-15 1982-06-15 Glaxo Group Limited Androstane carbothioates
US4578221A (en) 1980-04-23 1986-03-25 Glaxo Group Limited Androstane carbothioic acids
FI63672C (en) * 1980-05-19 1983-08-10 Orion Yhtymae Oy Foerfarande Foer framstaellning of a mixture of beklometasondipropionat Science triklorfluormetan eller dichlorodifluoromethane
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
GB8501015D0 (en) * 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
GB8820398D0 (en) 1988-08-27 1988-09-28 Fisons Plc Pharmaceutical formulation
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5776434A (en) * 1988-12-06 1998-07-07 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8900267D0 (en) * 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
DE3905726A1 (en) * 1989-02-24 1990-08-30 Hoechst Ag Aerosol and propellant for aerosols
US4940171A (en) * 1989-05-18 1990-07-10 Gilroy Gordon C Aerosol package having compressed gas propellant and vapor tap of minute size
IL95590A (en) * 1989-09-08 1996-06-18 Glaxo Group Ltd Pharmaceutical compositions comprising salmeterol and fluticasone propionate
GB2235627B (en) 1989-09-08 1993-09-01 Glaxo Group Ltd Inhalation medicaments for treating respiratory disorders
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
GB8921222D0 (en) * 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
IL97065A (en) * 1990-02-02 1994-01-25 Fisons Plc Aerosol propellant compositions
DE4003272A1 (en) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg New gas mixtures and their use in medicine preparations
DE4003270A1 (en) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg New speed gases and their use in medicine preparations
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
DE69131867D1 (en) * 1990-03-23 2000-01-27 Minnesota Mining & Mfg Use of soluble fluorine-containing surfactants for the preparation of aerosol preparations metered dose
US5126123A (en) * 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
EP0536250B1 (en) * 1990-06-28 2000-09-06 Glaxo Wellcome Inc. Aerosol drug formulations
BR9106595A (en) * 1990-06-29 1993-04-20 Fisons Plc Pressurized aerosol composition
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
WO1992006675A1 (en) * 1990-10-18 1992-04-30 Minnesota Mining And Manufacturing Company Aerosol formulation comprising beclomethasone 17,21 dipropionate
GB9024366D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
GB9024365D0 (en) 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
US5290539A (en) * 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5182097A (en) 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
JPH04316448A (en) * 1991-04-12 1992-11-06 Iwatani Internatl Corp Production of carrot fine powder
DK0656207T4 (en) * 1991-06-10 2009-11-30 Schering Corp Aerosol formulations without chlorofluorocarbon compounds
ES2180592T3 (en) * 1991-06-10 2003-02-16 Schering Corp Free aerosol formulations chlorofluorocarbons.
ES2123576T3 (en) * 1991-12-12 1999-01-16 Glaxo Group Ltd Medicines.
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
AU663906B2 (en) * 1991-12-12 1995-10-26 Glaxo Group Limited Medicaments
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5744123A (en) 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5916540A (en) * 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5683676A (en) 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
PT1086688E (en) * 1991-12-18 2004-06-30 Minnesota Mining & Mfg Suspended aerosol formulations
US20030103907A1 (en) * 1991-12-18 2003-06-05 Schultz Robert K. Suspension aerosol formulations
US5202110A (en) * 1992-01-22 1993-04-13 Virginia Commonwealth University Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants
GB9202519D0 (en) 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
US5833950A (en) 1992-07-31 1998-11-10 Glaxo Group Limited Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate
US6013245A (en) * 1995-01-26 2000-01-11 Glaxo Group Limited Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant
JPH0855956A (en) 1994-08-10 1996-02-27 Fuji Electric Co Ltd Drive circuit device module
GB9510750D0 (en) 1995-05-26 1995-07-19 Zeneca Ltd Chemical process
US5603918A (en) * 1995-06-09 1997-02-18 Boehringer Ingelheim Pharmaceuticals, Inc. Aerosol composition of a salt of ipratropium and a salt of albuterol
TW382127B (en) * 1996-08-30 2000-02-11 Sony Corp Magnetic recording medium and cleaning tape
US6306396B1 (en) * 1996-10-01 2001-10-23 Corixa Corporation Compounds and methods for the diagnosis and treatment of B. microti infection
BR0208012A (en) * 2001-03-20 2004-03-02 Glaxo Group Ltd Uses of at least two drug and HFA propellant and at least one farmaceêutica composition, and packaged for treating asthma inhaler

Also Published As

Publication number Publication date
US20090188491A1 (en) 2009-07-30
EP1066828B9 (en) 2008-03-26
NO20001227L (en) 1994-06-10
CY2441B1 (en) 2004-11-12
DE122006000020I1 (en) 2011-12-01
RU94030722A (en) 1996-10-20
GR3036476T3 (en) 2001-11-30
EP1857101A2 (en) 2007-11-21
IL104068A (en) 1998-10-30
DE69233712D1 (en) 2007-10-31
US5676929A (en) 1997-10-14
US20050089477A1 (en) 2005-04-28
CA2447510C (en) 2007-07-03
EP0756868A2 (en) 1997-02-05
AP402A (en) 1995-08-22
AT227975T (en) 2002-12-15
AT163539T (en) 1998-03-15
BG98803A (en) 1995-02-28
PT990437E (en) 2003-04-30
PT1066828E (en) 2003-10-31
IS1709B (en) 1998-12-16
IL104068D0 (en) 1993-05-13
BG64539B1 (en) 2005-07-29
DK1066828T4 (en) 2007-02-26
BG102689A (en) 1999-02-26
NZ246044A (en) 1996-01-26
DE69232856T3 (en) 2009-07-09
ES2188092T5 (en) 2009-04-01
AT296617T (en) 2005-06-15
US6303103B1 (en) 2001-10-16
CZ143094A3 (en) 1995-03-15
EP0990437A1 (en) 2000-04-05
DE69233519D1 (en) 2005-07-07
CA2362539A1 (en) 1993-06-24
CA2303685C (en) 2002-02-12
EP1440686A1 (en) 2004-07-28
US6238647B1 (en) 2001-05-29
DK0616523T3 (en) 1998-09-28
AP9200461A0 (en) 1993-01-31
BG62119B1 (en) 1999-03-31
AU3085092A (en) 1993-07-19
AU663904C (en) 2005-05-19
RU2129424C1 (en) 1999-04-27
EP1066828A1 (en) 2001-01-10
CA2402300A1 (en) 1993-06-24
JPH07502033A (en) 1995-03-02
DK1275375T3 (en) 2005-08-22
WO1993011743A1 (en) 1993-06-24
CY2566B1 (en) 2008-07-02
NO325422B1 (en) 2008-04-21
EP1857101A3 (en) 2008-10-08
DE69224656T2 (en) 1998-07-23
DE69231857T2 (en) 2001-11-29
JPH11310533A (en) 1999-11-09
HU227383B1 (en) 2011-05-30
ES2188092T3 (en) 2003-06-16
US6251368B1 (en) 2001-06-26
CZ287039B6 (en) 2000-08-16
HU9401742D0 (en) 1994-09-28
HK1054500A1 (en) 2005-12-30
HK1012988A1 (en) 2002-01-04
DK1440686T3 (en) 2008-01-21
OA9926A (en) 1994-09-15
EP1287820A1 (en) 2003-03-05
AT421315T (en) 2009-02-15
DE69233076D1 (en) 2003-06-26
ES2242823T3 (en) 2005-11-16
DE69232856D1 (en) 2003-01-02
AT373465T (en) 2007-10-15
EP1066828B2 (en) 2006-12-06
MX9207205A (en) 1993-11-01
CA2125667C (en) 2000-06-13
DE69224656D1 (en) 1998-04-09
EP0990437B2 (en) 2008-10-22
IS3957A (en) 1993-06-13
EP1440686B1 (en) 2007-09-19
CA2586146C (en) 2009-01-20
PT1275375E (en) 2005-09-30
CY2134B1 (en) 2002-06-21
ES2113444T3 (en) 1998-05-01
HU211671A9 (en) 1995-12-28
EP1275375B1 (en) 2005-06-01
HU227681B1 (en) 2011-11-28
TW232654B (en) 1994-10-21
NO942185L (en) 1994-06-10
DK0990437T3 (en) 2003-03-10
RU2179037C2 (en) 2002-02-10
DK1287820T3 (en) 2009-05-18
DE69233076T3 (en) 2007-07-12
CY2602B2 (en) 2010-03-03
PT1440686E (en) 2007-12-19
DE69231857D1 (en) 2001-07-05
AT201587T (en) 2001-06-15
US5674472A (en) 1997-10-07
EP0616523B1 (en) 1998-03-04
DE69232856T2 (en) 2003-07-31
AT240716T (en) 2003-06-15
EP1287820B1 (en) 2009-01-21
US20030143163A1 (en) 2003-07-31
EP0756868A3 (en) 1997-02-26
AU663904B2 (en) 1995-10-26
DK1066828T3 (en) 2003-08-25
DE69233076T2 (en) 2004-03-18
ES2294386T3 (en) 2008-04-01
SK279920B6 (en) 1999-05-07
ES2199739T3 (en) 2004-03-01
EP0990437B1 (en) 2002-11-20
CY2591B2 (en) 2009-11-04
CY2493B1 (en) 2005-09-02
EP0616523A1 (en) 1994-09-28
CA2362539C (en) 2003-02-04
HK1004711A1 (en) 2000-07-28
SK67494A3 (en) 1995-03-08
JP3026840B2 (en) 2000-03-27
DE69233755D1 (en) 2009-03-12
US7498020B2 (en) 2009-03-03
DK0990437T4 (en) 2009-02-16
CA2586146A1 (en) 1993-06-24
CA2303685A1 (en) 1993-06-24
CA2654849A1 (en) 1993-06-24
ES2158988T3 (en) 2001-09-16
US20040136920A1 (en) 2004-07-15
ES2319873T3 (en) 2009-05-14
GEP20002253B (en) 2000-07-10
EP0756868B1 (en) 2001-05-30
DE69233519T2 (en) 2006-04-27
NO942185D0 (en) 1994-06-10
PT1287820E (en) 2009-03-11
NO20065102L (en) 1994-06-10
DE69233712T2 (en) 2008-06-19
US20020028183A1 (en) 2002-03-07
CA2402300C (en) 2005-06-28
ES2199739T5 (en) 2007-06-16
HUT67534A (en) 1995-04-28
NO20001227D0 (en) 2000-03-09
NO307864B1 (en) 2000-06-13
EP1275375A1 (en) 2003-01-15
HU0800468D0 (en) 2008-09-29
DK0756868T3 (en) 2001-09-10
EP1066828B1 (en) 2003-05-21
PT756868E (en) 2001-11-30
CA2447510A1 (en) 1993-06-24

Similar Documents

Publication Publication Date Title
CA2014889C (en) Intra-rectal pharmaceutical foam compositions
EP0990437B1 (en) Aerosol compositions
CA2074495C (en) Propellant compositions
CA2280099C (en) Medical aerosol formulations
US5378451A (en) Topical medicinal pressurized aerosol compositions and method of preparation, method of use and article of manufacture thereof
JP2769925B2 (en) Aerosol formulations comprising beclomethasone 17,21 dipropionate
US5474759A (en) Non-chlorofluorocarbon aerosol formulations
KR100970531B1 (en) Pharmaceutical compositions for the treatment of asthma
CA2352484C (en) Pressurised metered dose inhalers (mdi)
AU676390B2 (en) A medicinal aerosol formulation
AU631155B2 (en) Medicinal aerosol formulations
AU654397B2 (en) Pressurised aerosol compositions
RU2120285C1 (en) Aerosol pharmaceutic composition, bottle for storage and delivery of aerosol pharmaceutic composition, method of treatment of respiratory diseases, composition preparation method
DE60114571T2 (en) Formulations containing an anticholinergic agent for the treatment of chronic obstructive pulmonary disease
EP0636362B1 (en) The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
JP3280974B2 (en) Pharmaceuticals
US5993781A (en) Fluticasone propionate nebulizable formulations
FI122395B (en) Use of an aqueous suspension of mometasone furoate in the manufacture of a medicament
JP3210012B2 (en) Pharmaceuticals
EP0216856B1 (en) Aerosol foam
DE69233659T2 (en) Chlorofluorocarbon-free aerosol formulations
CA2355932C (en) Pharmaceutical aerosol formulations containing fluoroalkanes, budesonide and formoterol
EP0983058B1 (en) Medicinal aerosol products
EP2201964B1 (en) Formoterol superfine formulation
EP0414920B1 (en) Aerosol preparation for external use

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20121204